Breaking News

BrainStorm, Mayo Clinic Enter ALS Trial Pact

To conduct Phase II trial of NurOwn in ALS

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases, has signed a definitive agreement with the Mayo Clinic in Rochester, MN to conduct its Phase II trial of NurOwn in amyotrophic lateral sclerosis (ALS). Mayo’s Human Cell Therapy Lab will manufacture the NurOwn cells for the clinical trial. Additional sites for the multi-center trial include the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.   “W...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters